Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma

This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of Rituximab, Lenalidomide combined with high-dose Methotrexate and Temozolomide (RL-MT) in the first-line treatment for patients with primary central nervous system lymphoma.

Trial Details

NCT ID

NCT04737889

Phase

PHASE2

Sponsor

Henan Cancer Hospital

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

Rituximab
Lenalidomide
Methotrexate
Temozolomide

Locations (sample)

Zhengzhou, Henan, China|34.75778,113.64861

Key Eligibility Criteria

Age between 18 to 70 years old (including 18 and 70)
Diagnosed as primary central nervous system lymphoma (limited to the brain, spinal cord, meninges and eyeballs, without involvement of other parts)
Having not received anti-tumor therapy before enrollment (except for tumor resection and biopsy and the use of glucocorticoids to reduce central ne…
Having at least one measurable lesions

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →